top of page

Digestive Health

Pancreatic Lesions

Epidemiology & Progression:

Incidental pancreatic cysts are found in 2-15% of abdominal imaging studies, increasing with age [22]. Most are benign, but some (e.g., IPMNs, MCNs) have malignant potential. Progression risk varies by cyst type and features (size, duct dilation, mural nodules). Solid pancreatic lesions are less common but carry a higher malignancy risk, necessitating prompt evaluation [AGA Guideline on Pancreatic Cysts, 23].

Clinical Value:

Tracking pancreatic lesions according to guidelines (e.g., AGA, ACR) allows for appropriate surveillance or workup based on risk factors [22, 23]. This facilitates early detection of pancreatic cancer or high-risk precursor lesions when surgical resection may be curative. Failure to track can lead to missed malignancies or delayed diagnosis at an advanced stage with poor prognosis [24].

Return on Investment (ROI):

Guideline-adherent management of pancreatic lesions drives appropriate use of advanced imaging (MRI/MRCP, EUS) and specialist referrals. Based on proprietary modeling for a medium-sized hospital system, Thynk Health's tracking can capture an estimated $1.9 million in additional net revenue over five years (70% vs 30% capture) through diagnostics, EUS-FNA, and potential surgical interventions (e.g., Whipple procedure), improving outcomes for high-risk lesions [Thynk Health ROI Data, 2025].

Feature List:

  • NLP for Cyst/Mass Characteristics: Extracts lesion type (cyst vs. solid), size, features (mural nodules, duct dilation) per AGA/ACR guidelines. 

  • Guideline Integration (AGA/ACR): Applies appropriate follow-up pathways based on extracted features. 

  • Advanced Imaging Scheduling: Facilitates scheduling of follow-up MRI/MRCP or EUS based on recommendations. 

  • GI/Surgical Oncology Referral Workflow: Triggers referrals for high-risk lesions. 

Gallbladder Polyps

Epidemiology & Progression:

Gallbladder polyps are found in approximately 5% of the adult population undergoing abdominal ultrasound [25]. The vast majority are benign cholesterol polyps. However, polyps >10 mm, those demonstrating rapid growth, or occurring in patients >50 years old carry an increased risk of malignancy (gallbladder cancer) [26, European Guidelines ESGAR]. Malignancy risk is low overall (<5%) but significant for larger lesions [25].

Clinical Value:

Tracking gallbladder polyps allows for risk stratification based on size and patient factors, guiding decisions between surveillance ultrasound and cholecystectomy [26]. This approach aims to remove potentially malignant polyps while avoiding unnecessary surgery for benign lesions. Untracked polyps, especially larger ones, risk progression to gallbladder cancer, which has a poor prognosis if diagnosed late [27].

Return on Investment (ROI):

Managing gallbladder polyps according to guidelines involves surveillance ultrasounds and selective referrals for surgical consultation and cholecystectomy. While specific ROI data isn't provided in the memory, effective tracking prevents patient leakage for surveillance and necessary surgeries. This likely generates hundreds of thousands to low millions of dollars in net revenue over 5 years for a medium system through retained imaging and surgical procedures [Educated Estimate based on Procedure Volume/Costs, 26].

Feature List:

  • NLP for Polyp Size: Extracts polyp size measurements from ultrasound or CT reports. 

  • Size/Age-Based Risk Logic: Applies logic based on size (>10mm) and age (>50) to flag higher-risk polyps per guidelines (e.g., ESGAR). 

  • Ultrasound Surveillance Scheduling: Manages follow-up ultrasound schedules for smaller polyps. 

  • Surgical Referral Workflow: Triggers referrals for cholecystectomy based on risk criteria. 

Splenic Lesions

Epidemiology & Progression:

Incidental splenic lesions are relatively common, found on up to 1-2% of abdominal CT scans [28]. Most are benign (cysts, hemangiomas, hamartomas). Malignant lesions (lymphoma, metastases) are less frequent but clinically significant. Progression depends on the underlying cause; benign lesions rarely progress, while malignancies require specific treatment [ACR White Paper on Managing Incidental Findings Part 1, 29]. 

Clinical Value:

Characterizing and tracking splenic lesions according to ACR guidelines helps differentiate benign from potentially malignant findings, often using follow-up imaging (CT, MRI, PET/CT) or biopsy in specific cases [29]. This ensures timely diagnosis and treatment for malignancies like lymphoma or metastases while avoiding unnecessary workup for benign lesions. Failure to track potentially malignant lesions can delay critical diagnoses [29].

Return on Investment (ROI):

Appropriate management involves follow-up imaging and potential hematology/oncology referrals. Specific ROI for splenic lesions is not detailed in the provided memory data (shows zero/negligible tracked ROI in summaries). However, ensuring appropriate follow-up imaging (MRI, PET/CT) and capturing downstream referrals for workup of suspicious lesions (e.g., biopsy, systemic workup for lymphoma/metastasis) would prevent revenue loss, likely contributing tens to hundreds of thousands of dollars annually to a medium system [Educated Estimate based on ACR Guidelines/Workup Costs, 29].

Feature List:

  • NLP for Lesion Characteristics: Extracts size and basic characteristics (e.g., cystic, solid) from reports. 

  • ACR Guideline Integration: Applies follow-up recommendations based on size and patient history (e.g., known malignancy). 

  • Follow-up Imaging Scheduling: Manages scheduling for recommended MRI or PET/CT. 

  • Hematology/Oncology Referral Trigger: Flags suspicious lesions for specialist review. 

Hiatal Hernia

Epidemiology & Progression:

Hiatal hernias (HH) are very common, affecting up to 60% of individuals over age 50, though many are asymptomatic [30]. They occur when the upper stomach pushes through the diaphragm. Most are Type I (sliding) and small. Progression involves potential enlargement or development of complications like GERD, esophagitis, Barrett's esophagus, or rarely, volvulus/strangulation with large paraesophageal hernias (Types II-IV) [31].

Clinical Value:

While often incidental, documenting HH size and type is important. Large or symptomatic hernias warrant clinical correlation and potential gastroenterology/surgical referral for management of symptoms (e.g., severe GERD) or prevention of complications [31]. Tracking changes over time can inform management decisions. Ignoring large or symptomatic hernias can lead to chronic complications or acute surgical emergencies.

Return on Investment (ROI):

Management involves potential endoscopy, pH/manometry studies, and anti-reflux surgery for symptomatic or complicated cases. No direct ROI data is provided in memory. However, tracking ensures patients with significant or symptomatic HH are appropriately referred for GI workup and potential surgical repair. Retaining these diagnostic procedures and surgical interventions likely generates hundreds of thousands of dollars over 5 years for a medium system [Educated Estimate based on Procedure Volume/Costs, 31].

Feature List:

  • NLP for Hernia Type/Size: Extracts hernia type (sliding, paraesophageal) and potentially size indicators. 

  • Symptom Correlation (Potential Integration): Could potentially link imaging findings with documented symptoms in EHR for better context (requires advanced integration). 

  • GI/Surgical Referral Workflow: Facilitates referrals for large or symptomatic hernias. 

Colon Diverticulitis

Epidemiology & Progression:

Diverticulosis (presence of diverticula) is extremely common, affecting >50% of adults over 60 in Western countries [32]. Diverticulitis (inflammation/infection) occurs in 10-25% of those with diverticulosis during their lifetime. Recurrence after an initial episode is common (up to 30-40%). Complicated diverticulitis (abscess, perforation, fistula, stricture) occurs in ~15% of acute cases [AGA Guideline on Diverticulitis, 33].

Clinical Value:

Tracking episodes of diverticulitis, especially complicated cases identified on imaging (e.g., CT findings of abscess/perforation), is crucial for guiding management (antibiotics, drainage, surgery) and assessing risk of recurrence or complications [33]. Follow-up colonoscopy after an episode is recommended to exclude underlying malignancy. Failure to track history and severity can lead to suboptimal management or delayed recognition of complications [33].

Return on Investment (ROI):

Management involves imaging, hospital admissions, interventional radiology procedures (drainage), and potential colorectal surgery (elective or emergent colectomy). No direct ROI data is provided in memory. Tracking ensures appropriate follow-up (e.g., post-diverticulitis colonoscopy) and identifies candidates for elective surgery, preventing costly emergent admissions. Retaining these procedures likely generates significant revenue, potentially millions over 5 years for a medium system [Educated Estimate based on Admission/Procedure Costs, 33]. 

Feature List:

  • NLP for Complications: Identifies report findings indicating complicated diverticulitis (abscess, perforation). 

  • Follow-up Colonoscopy Tracking: Creates reminders/tasks for post-diverticulitis colonoscopy. 

  • Colorectal Surgery Referral Workflow: Flags patients with complicated or recurrent episodes for surgical consult. 

Important Note on ROI: The Return on Investment (ROI) figures presented are derived from Thynk Health's proprietary performance data analysis. These calculations are based on models simulating a medium-sized hospital system processing approximately 600,000 CT scans annually through emergency departments and utilizing multispecialty guidelines for follow-up care pathways and associated downstream revenue capture. Actual ROI may vary based on specific institutional factors, patient populations, and payer mix.  

References: 
[22] Elta, G. H., et al. (2018). ACG clinical guideline: diagnosis and management of pancreatic cysts. American Journal of Gastroenterology. 
[23] Berland, L. L., et al. (2017). Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. Journal of the American College of Radiology. (Covers Pancreas) 
[24] Scheiman, J. M., et al. (2007). Screening for pancreatic cancer in high-risk individuals. Gastroenterology. 
[25] Corwin, M. T., et al. (2011). Incidental gallbladder polyps: when to resect and when to observe. American Journal of Roentgenology. 
[26] Wiles, R., et al. (2017). Management of gallbladder polyps. World Journal of Gastroenterology. / Foley, K. G., et al. (2021). ESGAR consensus statement on the imaging and management of gallbladder polyps. European Radiology. 
[27] Hundal, R., & Shaffer, E. A. (2014). Gallbladder cancer: epidemiology and outcome. Clinical epidemiology. 
[28] Ghonge, N. P., et al. (2010). Incidental splenic lesions. Indian Journal of Radiology and Imaging. 
[29] Berland, L. L., et al. (2010). Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. Journal of the American College of Radiology. (Covers Spleen, Liver, Adrenal, Renal) 
[30] Jones, M. P. (2015). Evaluation and treatment of hiatal hernias. Surgical Clinics. 
[31] Kohn, G. P., et al. (2013). Guidelines for the management of hiatal hernia. SAGES. 
[32] Strate, L. L., & Morris, A. M. (2019). Epidemiology, pathophysiology, and treatment of diverticulitis. Gastroenterology. 
[33] Peery, A. F., et al. (2015). AGA technical review on the management of acute diverticulitis. Gastroenterology. 

bottom of page